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“Far and away the best prize that life has to offer 
 is the chance to work hard at work worth doing.” 
Theodore Roosevelt 
 
  
  
  
ABSTRACT 
Vaccination has been extremely successful for the control of many infectious diseases. 
However, efficient vaccines are still not available against diseases such as HIV, hepatitis C, 
malaria and tuberculosis. For these diseases, the traditional vaccine approaches are not 
feasible, and thus new vaccine technologies are needed. Some platforms that are being 
developed for this purpose include virus vectors and DNA vaccines. In addition, combining 
different vaccine modalities into heterologous prime-boost regimens induces antigen-specific 
immune responses that are greatly increased compared to homologous prime-boost 
immunization. 
In this thesis, we evaluated the use of alphavirus replicons as a vaccine platform and 
characterized antigen-specific immune responses induced in mice and rhesus macaques. 
Alphavirus replicons can be administered either as viral particles (VREP), or as naked DNA 
(DREP) or RNA (RREP). We used both model antigens (papers II and IV) and HIV 
antigens that are in clinical development (papers I and III). 
We show in paper I that antigen-specific CD8+ T cell responses induced by DREP can be 
further increased by delivery with intradermal electroporation. These responses were superior 
in magnitude to those induced by a conventional DNA vaccine and required lower doses. We 
also showed in mice and macaques that priming with DREP rather than conventional DNA 
prior to a heterologous boost with a poxvirus or adenovirus vector resulted in stronger 
immune responses characterized by multifunctional T cells. In paper II, we characterize the 
kinetics and memory phenotypes of CD8+ T cell responses induced by VREP and DREP. We 
show how altering factors such as timing and dose affects the magnitude and phenotype of 
the resulting immune response. In addition, we characterize the phenotypes of T cell 
responses induced by different heterologous boosters given after a DREP prime. For 
example, a poxvirus vector boost favored expansion of effector memory T cells. In paper III, 
we expand the heterologous prime-boost studies and explore the outcome of altering the 
number of DREP prime immunizations prior to a poxvirus and/or protein antigen boost. We 
demonstrate that a single prime with a low dose of DREP was sufficient for induction of 
antigen-specific T cells that were expanded by a poxvirus boost and antibody responses 
boosted by protein antigen. By boosting with poxvirus together with protein, both arms of 
adaptive immunity were induced. In paper IV, we use VREP as an adjuvant for antibody 
responses against a co-immunized protein antigen. We demonstrate that incorporating the 
innate immune stimulant flagellin into the replicon enhances its adjuvant potency, resulting in 
augmented antigen-specific antibody responses. 
In conclusion, we have characterized immune responses induced by alphavirus replicons 
administered as VREP or DREP and shown that DREP is an excellent prime of T cell and 
antibody responses prior to a heterologous boost immunization. These results strongly 
support further clinical testing of alphavirus replicon vaccines.  
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1 INTRODUCTION 
1.1 VACCINES 
Vaccines are considered one of the greatest medical successes in history and have had a 
tremendous worldwide impact on reduction of morbidity and mortality of infectious diseases. 
Some of the earliest documented attempts at immunization stem from 17th century China, 
where the variolation method was used. This involved inoculation against smallpox (variola) 
by introducing powdered scabs derived from smallpox pustules into the nose. Variolation was 
first introduced in Europe in 1721 by Lady Montagu, who had observed the technique being 
practiced in Constantinople. Although the treatment had a death rate of 2-3%, this was far 
lower than the 30% case-fatality rates that occurred during smallpox outbreaks. 
The first demonstration of vaccination, i.e. controlling an infectious disease without actually 
transmitting the disease, was performed by Edward Jenner in 1796. Jenner had noticed that 
milkmaids who had contracted cowpox were immune to smallpox. He then demonstrated that 
transfer of material from human pustular lesions caused by cowpox into the skin of another 
person gave protection from subsequent infection with smallpox. This material was named 
vaccine and the process vaccination from the latin vacca, meaning cow. About a century 
later, Louis Pasteur broadened the definition to include preventive inoculation with other 
agents. 
Today, smallpox has been eradicated from the world. Vaccines have also been successful in 
controlling numerous other viral diseases. For example, vaccination has reduced the number 
of cases of poliomyelitis by 99%. This disease is now also targeted for eradication by the 
World Health Organization. Other viral diseases against which vaccines have been developed 
include yellow fever, hepatitis B, influenza, measles, mumps, rubella, rabies and rotavirus 
(1). 
Despite the enormous progress that has occurred since Jenner’s first demonstration of 
vaccination, efficient vaccines are still not available against infectious diseases such as 
human immunodeficiency virus (HIV), hepatitis C, tuberculosis and malaria. For these 
diseases, the vaccine approaches that are used against other infectious diseases have not been 
successful or are not feasible. Therefore, new types of vaccines are being developed and 
characterized in an attempt to rationally target these diseases. 
1.2 IMMUNOLOGY OF VACCINATION 
The goal of vaccination is to induce long-lived immunity against a disease without causing 
the disease itself. When the first vaccines were developed, little was understood of the 
mammalian immune system. Today, we understand more about the components and 
functions of the immune system and protective mechanisms. Vaccines mimic natural 
infection in that they stimulate nonspecific innate immune responses that lead to induction of 
pathogen-specific adaptive immune responses. Innate responses are quick, usually occurring 
within minutes to hours after initiation of an infection, whereas adaptive immune responses 
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take several days to form. Adaptive responses contract after clearance of antigen and persist 
as immunological memory that upon exposure will protect an individual from subsequent 
infection with that pathogen. 
1.2.1 Innate immunity 
The innate immune system is the first line of defense that pathogens or vaccines encounter 
after crossing physical barriers such as skin. Antigen-presenting cells (APCs) such as 
dendritic cells (DCs) are innate immune cells that patrol the body. These cells are activated 
upon exposure to a pathogen or vaccine with sufficient “danger signals” and migrate to 
secondary lymph nodes where they activate antigen-specific T and B cells. Recent insights 
into the importance of triggering innate immune responses for inducing and shaping adaptive 
immune responses have led to an interest in exploiting this knowledge for the design of novel 
vaccine adjuvants (covered in section 1.3.3). 
Cells of the innate immune system use pattern recognition receptors (PRRs) to sense 
conserved structural and functional molecules of pathogens, known as pathogen-associated 
molecular patterns (PAMPs). In addition, PRRs detect molecules derived from necrotic or 
traumatized host cells, known as damage-associated molecular patterns (DAMPs). Signaling 
through PRRs triggers signaling cascades that result in innate responses such as nuclear 
factor kappa B (NF-κB)-dependent cytokine responses, interferon regulatory factor (IRF)-
dependent type I interferon (IFN) responses and inflammasome / caspase-1-dependent 
interleukin (IL)-1β responses (2). These responses keep the infection under initial control and 
play a critical role in inducing and shaping adaptive immune responses. Several families of 
PRRs have been identified, including the transmembrane Toll-like receptors (TLRs) and the 
cytoplasmic retinoic acid inducible gene I (RIG-I)-like receptors (RLRs), Nod-like receptors 
(NLRs), and DNA-sensing molecules (Table 1). 
 
Table 1. Pattern recognition receptors 
PRR family Examples Location Natural ligand 
TLRs TLR1/2/6 Cell surface Lipoproteins 
TLR3 Endosome dsRNA 
TLR4 Cell surface LPS 
TLR5 Cell surface Flagellin 
TLR7/8 Endosome ssRNA 
TLR9 Endosome Unmethylated CpG DNA 
RLRs RIG-I Cytoplasm Uncapped ssRNA, short dsRNA 
MDA5 Cytoplasm Long dsRNA 
NLRs NLRC4 Cytoplasm Flagellin 
DNA sensors cGAS Cytoplasm dsDNA 
  
  3 
1.2.1.1 TLRs 
TLRs were the first identified and today most well characterized family of PRRs. These 
receptors recognize distinct PAMPs derived from viruses, bacteria, mycobacteria, fungi and 
parasites, including lipoproteins (detected by TLR1, TLR2 and TLR6), double-stranded RNA 
(dsRNA) (TLR3), lipopolysaccharide (LPS) (TLR4), flagellin (TLR5), single-stranded RNA 
(ssRNA) (TLR7 and TLR8) and unmethylated CpG DNA (TLR9). The TLRs that recognize 
nucleic acids are located in endosomal compartments, while the other TLRs are located on 
cell surfaces. TLRs are expressed by innate immune cells such as DCs and macrophages, as 
well as nonimmune cells such as epithelial cells (3, 4). 
All TLRs except TLR3 signal through the adaptor molecule myeloid differentiation primary-
response protein 88 (MyD88), ultimately leading to the translocation of NF-κB into the 
nucleus, where it induces production of inflammatory cytokines such as tumor necrosis factor 
(TNF)-α, IL-6, IL-12 and pro-IL-1β. TLR3 and TLR4 are able to signal through a MyD88-
independent pathway, which leads to phosphorylation and activation of transcription factor 
IRF3, resulting in production of type I IFNs. TLR7 and TLR9 are primarily expressed in 
plasmacytoid DCs, which have the capacity to produce large amounts of type I IFNs in a 
MyD88-dependent manner (3). Signaling through TLRs plays an important role in activation 
of DCs, which then present antigens to lymphocytes, leading to induction of CD4+ T helper 
(Th) 1 and CD8+ T cell responses (5–7). In addition, TLRs shape antibody responses through 
intrinsic signaling in B cells (8). 
1.2.1.2 RLRs 
RLRs are RNA helicases that detect viral RNA in the cytosol. Unlike TLRs, these receptors 
are expressed by most cell types. The RLR family consists of three members: RIG-I, 
melanoma differentiation factor 5 (MDA5) and laboratory of genetics and physiology 2 
(LGP2). RIG-I recognizes uncapped 5’-triphosphate ssRNA and short dsRNA, whereas 
MDA5 recognizes longer dsRNA fragments. Signaling through RIG-I and MDA5 leads to 
activation of NF-κB and IRFs and subsequent production of proinflammatory cytokines and 
type I IFNs. LGP2 lacks the signaling domain present in RIG-I and MDA5 and exerts 
inhibitory and co-stimulatory functions, respectively, on these molecules (9–11). RLR 
signaling promotes CD8+ T cell responses (5, 12). 
1.2.1.3 NLRs 
The NLRs are a family of cytosolic receptors that sense a wide range of PAMPs and DAMPs 
(13). For example, NLRC4 recognizes bacterial flagellin (14, 15). Activation of NLRC4 
leads to formation of an inflammasome, a large multiprotein complex. This in turn activates 
caspase-1, which cleaves pro-IL-1β and pro-IL-18 into their mature forms. In addition, 
caspase-1 induces pyroptosis, a type of cell death characterized by rapid cell lysis with 
release of proinflammatory intracellular contents. These caspase-1 activities promote 
formation of Th1 and CD8+ T cell responses (16, 17). 
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1.2.1.4 DNA sensors 
The presence of DNA in the cytosol is a hallmark of certain infections or tissue damage 
caused by infection and is recognized by several DNA sensors that in turn induce type I IFN 
production. These sensors have only recently been discovered and are less well characterized. 
Signaling through many DNA sensors occurs through a central signaling cascade involving 
adaptor molecule STING, which then activates NF-κB and IRF3, leading to production of 
type I IFNs (18). So far, eleven different DNA sensors have been proposed with some 
examples being cyclic GMP-AMP synthase (cGAS) and DNA-dependent activator of IFN-
regulatory factors (DAI) (19–22). Cytosolic DNA sensors are important for the 
immunogenicity of DNA vaccines and their ability to induce T and B cell responses (5, 23). 
In addition, some DNA sensors including DAI and cyclic GMP-AMP possess adjuvant 
properties, i.e. they promote immune responses against co-immunized antigen (24, 25). 
1.2.1.5 Type I IFNs 
Many of the signaling pathways described above lead to the induction of type I IFNs, which 
are key mediators of antiviral responses and have derived their name for their function to 
“interfere” in viral replication. Type I IFNs are a group of proteins that includes more than 
ten different IFN-α, one IFN-β and several other related molecules that all bind to a common 
receptor, IFN-AR. All nucleated cells can both produce and respond to type I IFNs, although 
APCs and plasmacytoid DCs are key sources for type I IFN production. Signaling of type I 
IFNs causes the cell as well as surrounding tissue to enter an antiviral state characterized by 
the expression and antiviral activity of IFN-stimulatory genes (26, 27). Type I IFNs also have 
immunomodulatory effects on both innate and adaptive immune cells. In APCs such as DCs, 
type I IFNs stimulate upregulation of major histocompatibility complex (MHC) and 
costimulatory molecules, and promote cross-priming of CD8+ T cells (28–30). In addition, 
type I IFNs can directly activate DCs, T cells and B cells (31–34). 
1.2.2 Adaptive immunity 
Long-term immunological protection is provided by maintenance of adaptive immune cells 
that are pathogen-specific (35). Adaptive immune responses are mediated by cell-mediated 
immunity and humoral immunity. CD8+ T cells limit the spread of infectious agents by 
killing infected host cells or secreting antiviral cytokines. CD4+ Th cells produce cytokines 
and provide support for the generation and maintenance of B cells and CD8+ T cells. B cells 
produce antibodies that can bind to pathogens and prevent or reduce infections. 
Most of the currently licensed vaccines confer protection by induction of neutralizing 
antibodies (35, 36). However, control of HIV, malaria, hepatitis C virus and tuberculosis 
depends largely on CD4+ and CD8+ T cells, and thus future vaccines against these pathogens 
will rely on induction of potent and durable T cell responses as well as neutralizing antibodies 
(37–39). 
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1.2.2.1 T cell responses 
T cell responses are generated when DCs capture antigen in peripheral tissue, mature into an 
activated state and migrate to draining lymph nodes, where they present antigen-derived 
peptides on MHC molecules to T cells. The general notion is that CD8+ T cells recognize 
short peptide fragments 8-11 amino acids in length presented on MHC class I molecules, 
whereas CD4+ T cells recognize fragments 10-18 amino acids in length presented on MHC 
class II molecules. Peptides presented on MHC class I molecules are derived from 
endogenous proteins in the cytosol or from exogenous proteins in a process knows as cross-
presentation. MHC class II molecules present peptides derived from exogenous proteins. 
Recognition of peptide:MHC complexes by T cell receptors results in activation of the T cell 
if costimulation and cytokines such as type I IFN or IL-12 are simultaneously provided by the 
DC. 
Naïve T cells are present at low frequencies and expand to frequencies as high as 100,000-
fold higher after infection or vaccination (40) (Fig. 1). This “clonal expansion” phase lasts for 
7-10 days and is followed by a “clonal contraction” phase, which occurs after removal of the 
antigen, 2-4 weeks after vaccination, resulting in elimination of around 90% of effector cells. 
This is followed by the “maintenance of memory” phase, where a subset of effector T cells 
survives and is maintained as long-lasting memory T cells. 
CD4+ T cells can differentiate into several subsets of effector cells upon activation, such as 
Th1 or Th2, depending on the cytokines produced at the site of activation (35). In general, 
Th1 cells promote cell-mediated immunity in response to intracellular infection with viruses 
or some bacteria, whereas Th2 cells promote humoral immunity in response to extracellular 
pathogens such as parasites. Th1 cells secrete IFN-γ and TNF-α, which activate macrophages 
and support CD8+ T cell differentiation as well as maintenance of memory CD8+ T cells. Th2 
cells produce cytokines such as IL-4, which stimulates B cells and the production of 
neutralizing antibodies. More recently, other subsets such as Th17, Th9 and Th22 have been 
described. In addition, T follicular helper cells are a subset of CD4+ T cells present in 
germinal centers of lymph nodes that are crucial for development of B cell memory and long-
lived plasma cells (41). 
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Figure 1. Kinetics of antigen-specific T 
cell responses after infection or 
vaccination. Upon exposure to a pathogen 
or vaccine, T cells undergo massive 
expansion. After clearance of the antigen, 
around 90% of effector T cells die. 
Remaining T cells are maintained as a 
memory pool. 
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Activated CD8+ T cells differentiate into cytotoxic T cells that travel to sites of infection and 
mediate the killing of infected cells. Killing is mainly mediated by exocytosis of granules that 
contain granzymes and perforin that induce apoptosis of the target cell. In addition, effector 
CD8+ T cells secrete IFN-γ. CD8+ T cell responses correlate strongly with control of disease 
progression in viral diseases such as HIV infection. Although a clear correlate has not yet 
been defined, it appears that the magnitude of the HIV-specific CD8+ T cell response alone is 
not an effective measure of protective immunity. Instead, quality measures such as the ability 
of CD8+ T cells to produce multiple cytokines, such as IFN-γ, IL-2 and TNF-α, as well as 
cytotoxic function are important parameters in correlation with viral control (42–45). 
Protective immunity is also based on the phenotype of the memory T cell population that 
persists after the initial response has contracted. Memory T cells can be categorized into 
functionally different subpopulations based on phenotypic markers, the most well 
characterized subsets being central memory T (Tcm) and effector memory T (Tem) cells (46–
51). Tcm reside in secondary lymphoid organs and rapidly proliferate upon antigen 
encounter, whereas Tem migrate through nonlymphoid tissue and exert immediate effector 
functions against invading pathogens. The optimal type of response depends on the specific 
pathogen. For example, Tcm are important for control of systemic infections such as 
lymphocytic choriomeningitis virus (LCMV), which replicates in lymphoid organs (52–54). 
For chronic infections such as HIV, which replicates in the periphery, early control of viral 
spread by Tem is important (38, 55). More recently, resident memory T cells have been 
described as another memory subpopulation. These cells reside in nonlymphoid peripheral 
tissues such as lung, gut and skin and provide frontline protection against invading 
pathogens. 
Although Tem and Tcm are the most studied subsets of memory T cells, some other 
classifications have been proposed, such as that based on expression of CD27 and CD43 (56). 
Antigen-specific CD8+ T cells that are CD27+ CD43+ display a high proliferation rate, but 
this population disappears over time. Instead, a CD27+ CD43- population persists, 
characterized by a high recall capacity and the ability to migrate to mucosal sites. This CD27+ 
CD43- T cell phenotype has been associated with increased cytotoxic potential and control of 
infection with LCMV (57, 58). 
1.2.2.2 Antibody responses 
When B cells are stimulated with antigen in the presence of Th cells in lymphatic organs, 
they develop into high-affinity B cells through an affinity maturation process. These cells can 
then become antibody-producing cells or migrate to the bone marrow to become long-lived 
plasma cells or memory B cells. Most current vaccines mediate protection by induction of 
highly specific serum immunoglobulin G (IgG) antibodies that are neutralizing (35, 36, 59). 
Antibodies have several effector functions. Neutralizing antibodies bind to and block 
pathogens, rendering them unable to infect cells. Antibodies can also coat pathogens and 
promote their ingestion by phagocytes, a process called opsonization. This occurs through the 
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binding of antibodies to Fc receptors on phagocytes. Natural killer cells also express Fc 
receptors and can destroy infected cells coated with antibodies in a process called antibody-
dependent cellular cytotoxicity (ADCC). Coating of infected cells or pathogens by antibodies 
also renders them susceptible to lysis mediated by the complement system. 
Induction of broadly neutralizing antibodies that block viral entry into host cells will be an 
important feature in future vaccines against pathogens such as HIV (45). In addition, recent 
studies have implied an important role for non-neutralizing IgG antibodies that bind to HIV 
antigens on the surface of HIV-infected cells and recruit innate immune cells that have an Fc 
receptor such as natural killer cells, thereby mediating ADCC (60). 
In both humans and mice, there are four different subclasses of IgG, each contributing to 
humoral immunity in different ways. In mice, the IgG1 subclass is associated with a Th2-type 
response, whereas IgG2a is associated with a Th1 profile, including ADCC and complement 
activation (61, 62). 
1.3 NEW VACCINE STRATEGIES 
The first vaccines were prepared by attenuation or inactivation of an isolated infectious agent, 
without much knowledge on the correlates of protective immunity. Several other vaccine 
approaches have since then emerged, including the use of toxoid/protein, polysaccharide, 
glycoconjugate, recombinant protein and blood cell infusion vaccines. This has led to the 
development of vaccines against several different viruses and bacteria (63). Currently 
licensed vaccines are summarized in Table 2. 
Although the traditional approaches using live attenuated or inactivated organisms have been 
extremely effective against many diseases, they may not be feasible for pathogens such as 
HIV and hepatitis C virus. These pathogens differ from the viruses for which effective 
vaccines have been developed in that they cause chronic infection and have complex immune 
Table 2. Licensed vaccines for human use, by type 
Type of vaccine Licensed vaccines 
Live attenuated Smallpox, rabies, tuberculosis, yellow fever, polio (oral polio vaccine), measles, 
mumps, rubella, typhoid, varicella, rotavirus, influenza (cold adapted), zoster 
Inactivated whole 
organism 
Typhoid, cholera, plague, pertussis, influenza, typhus, polio (inactivated polio vaccine), 
rabies, Japanese encephalitis, tick-borne encephalitis, hepatitis A 
Toxoid/protein Diphteria, tetanus, acellular pertussis, anthrax, influenza subunit 
Polysaccharide Pneumococcus, meningococcus, Haemophilus influenzae B, typhoid 
Glycoconjugate Haemophilus influenzae B, pneumococcus, meningococcus 
Recombinant Hepatitis B, human papillomavirus, hepatitis E, cholera toxin B, meningococcus 
Blood cell infusion Prostate cancer 
Modified from (63). 
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evasion strategies as well as high genetic variability and mutation rates. Vaccination with live 
attenuated forms would be too risky with these pathogens due to the risk of establishing 
persistent infections. In addition, since infection with the wild type (WT) virus of these 
pathogens does not result in protective immunity, the immune responses that would be 
induced using the traditional approaches might not be desirable. 
Therefore, new vaccine technologies are being developed with the purpose of eliciting the 
type of immunity that is believed to be important for protection against the pathogen. With 
the recent increased knowledge of innate immune signaling and its effect on adaptive 
immune responses, vaccines can be rationally designed to induce strong T cell and antibody 
responses. New technologies include using viral or nucleic acid vectors for intracellular 
delivery of immunogens as well as novel adjuvants that trigger specific PRRs. Additionally, 
these platforms can be combined into heterologous prime-boost regimens to increase the 
magnitude and tailor the phenotype of immune responses. 
1.3.1 Viral vectored vaccines 
Recombinant viral vectored vaccines involve the use of safe and well-studied viruses as 
vectors with inserted antigen genes. The rationale is that the immune system will react to the 
vaccine as a natural virus infection due to the nature of the vector, which will then result in a 
strong response against the antigen. Viral vectors used in vaccines have often been attenuated 
by genetic deletions or by passaging through cell lines. Infection with viral vectors induces 
innate immune responses that are translated to potent adaptive immune responses. One 
potential limitation with viral vectors is the development of antivector immunity that can 
interfere with the effect of immunization. Antivector immunity can either be a result of 
previous natural infection with the virus that the vector is based on, or it can have developed 
from prior immunization with the same vector. 
Numerous different viruses have been developed for use as vaccine vectors. Some of these 
vectors and their attributes are listed in Table 3. The viruses that have been most studied in 
preclinical and clinical studies as vectors are poxviruses and adenoviruses. Both of these 
vectors were used in this thesis and will be discussed below. Alphavirus vectors were a main 
focus of this thesis and will be covered in section 1.4. 
1.3.1.1 Poxvirus vectors 
Poxviruses are dsDNA viruses that hold several advantages for use as vaccine vectors and 
have been widely tested in preclinical and clinical studies over the past two decades (64, 65). 
First, safety in humans has been tested extensively due to the mass vaccination against 
smallpox. Since smallpox vaccination ceased in the 1970s after eradication of smallpox was 
declared, prevalence of pre-existing antivector immunity is low in the population born after 
this time. In addition, clinical studies have shown that antivector immunity does not reduce 
immune responses elicited by poxvirus vectors (66). Poxvirus vectors can carry large gene 
inserts (up to 25 kb of foreign DNA), and as replication occurs in the cytoplasm, there is no 
risk of integration of viral DNA into the host genome. 
  9 
One of the most studied poxvirus vectors is modified vaccinia Ankara (MVA). MVA was 
obtained by passaging vaccinia virus in primary chicken embryo fibroblasts more than 570 
times. Through this process, MVA was highly attenuated and lost about 30 kb of DNA in 
deletions, mostly of genes encoding proteins with immunomodulatory properties that 
counteract host immune responses (67, 68). Thus, MVA has limited replication in host cells, 
and no infectious particles are formed after infection. In the 1970s, MVA was tested as a 
smallpox vaccine in >120,000 humans and was demonstrated to have a high safety profile 
(69). 
MVA induces a type I IFN response through multiple innate signaling pathways, including 
TLR2, TLR6, MDA5, NLR inflammasome formation and the newly discovered DNA sensor 
cGAS (70, 71). In preclinical and clinical studies, MVA has been shown to induce CD4+ and 
CD8+ T cell responses. A veterinary vaccine using MVA to deliver a rabies antigen has been 
licensed for use in wild animals, and MVA is currently in clinical trials for use in human 
vaccines against HIV, tuberculosis and malaria (64, 72–75). 
Other poxvirus vectors that are being evaluated in clinical trials include attenuated New York 
vaccinia (NYVAC) and canarypox virus (ALVAC). NYVAC was derived from the 
Copenhagen vaccinia strain by deletion of 18 open reading frames (ORFs) involved in 
Table 3. Examples of viral vaccine vectors 
Viral vector Advantages Limitations 
Poxvirus Known clinical safety (MVA) 
Large insert size 
No integration 
Possible pre-existing immunity 
Adenovirus Infects dividing and nondividing cells, including DCs 
Many strains available 
Pre-existing immunity (rAd5) 
Alphavirus High expression 
No pre-existing immunity 
No integration 
Safety concerns (VEE) 
Adeno-associated 
virus 
Physically stable, potential for oral use 
Non-pathogenic 
Possible integration 
Limited insert size 
Flavivirus Known clinical safety 
Possibility of chimeric viruses 
No integration 
Pre-existing immunity 
Herpesvirus Broad tropism Pre-existing immunity 
Safety concerns 
Measles virus Mucosal delivery possible 
Infects DCs and macrophages 
No integration 
Pre-existing immunity 
Vesicular stomatitis 
virus 
High expression 
Mucosal delivery possible 
No pre-existing immunity 
No integration 
Potentially neurovirulent 
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virulence and host range. Clinical trials have assessed NYVAC as an HIV vaccine and shown 
that it especially works well as a boosting agent after a DNA vaccine prime, resulting in 
induction of polyfunctional T cell responses (76). ALVAC was derived from a canarypox 
virus that had been passaged 200 times in chicken embryo fibroblasts, and was the priming 
component of the recent phase III RV144 trial, which for the first time showed modest but 
transient protective efficacy of an HIV vaccine (77). 
Since poxvirus vectors have a restrictive replication capacity and have thus far shown limited 
efficacy in clinical trials, new poxvirus vector variants are being developed with the purpose 
of enhancing their immunogenicity (78). For example, expression of cytokines such as IL-12 
or IFN-γ from MVA induces augmented cellular immune responses against antigen 
expressed from co-immunized MVA (79). Another approach that is being evaluated is 
deletion of immunomodulatory genes still present in the poxvirus vector that can interfere 
with induction of immune responses. For instance, deletion of a gene encoding a TLR 
antagonist (A46R) in NYVAC resulted in increased magnitudes of CD4+ and CD8+ T cell 
responses against HIV antigens (80). Also, an MVA vector with deletions in genes involved 
in inhibition of type I IFN signaling (C6L and K7R) similarly induced enhanced HIV-specific 
T cell responses (81). An MVA vector with deletions in A46R, C6L and K7R was used to 
create an MVA-vectored Chikungunya virus (CHIKV) vaccine candidate that induced 
protection in mice after only one immunization (82). Administration of this vaccine candidate 
after a DNA replicon prime resulted in massive expansion of CHIKV-specific T cell 
responses (83). In paper II, we investigate the phenotype of these responses. 
A different strategy is to insert optimized antigens into the poxvirus vector rather than 
modifying the vector backbone itself. For example, NYVAC was constructed to express 
optimized HIV antigens. In one construct, Env was expressed and secreted as a trimer, while 
another construct expressed a Gag-Pol-Nef of which Gag induced formation of virus-like 
particles in infected cells (84). These constructs induced enhanced innate immune responses 
in human cells and antigen-specific immune responses in mice. 
1.3.1.2 Adenovirus vectors 
Adenovirus is a well-characterized dsDNA virus with several features that make it an 
attractive vector. It can infect many nondividing and dividing cell types including DCs, has a 
high safety profile and exhibits high transgene expression (85, 86). Adenoviruses induce type 
I IFNs via TLR9 and cytoplasmic PRRs including cGAS (87, 88), resulting in strong T cell 
responses (85, 89, 90). Several strains have been used as vectors in preclinical and clinical 
studies, with recombinant human adenovirus (rAd) serotype 5 (rAd5) being the most widely 
studied strain. One limitation with the use of adenoviruses is the prevalence of pre-existing 
immunity due to natural adenovirus infection. For example, neutralizing antibodies against 
rAd5 can be detected in 60-70% of people in Europe and the USA, and in 90% of people in 
various regions of Africa (91, 92). 
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rAd5 was tested in humans in the STEP study, a proof-of-concept HIV vaccine clinical trial 
in phase IIb with the purpose of inducing cell-mediated immune responses for prevention of 
HIV-1 infection. The study compared rAd5 encoding HIV-1 clade B gag/pol/nef with 
placebo. The trial was stopped in 2007 due to lack of efficacy. Posthoc analyses have 
revealed that vaccinated individuals who were seropositive for rAd5 prior to enrollment in 
the study in fact had a higher HIV acquisition rate compared to the placebo group during the 
first 18 months after vaccination (93, 94). The mechanisms responsible for this increased risk 
of infection are still unclear, although it has been suggested that it was due to activation of 
rAd5-specific memory CD4+ T cells after vaccination, which would render these cells 
susceptible to HIV infection (95). 
To circumvent problems with pre-existing vector immunity, novel vectors have been derived 
from less common human adenovirus serotypes such rAd25 and rAd35, or from adenoviruses 
that normally infect chimpanzees, for example chimpanzee adenovirus (ChAd) serotype 63 
(ChAd63) (74, 92, 96–99). These are being assessed in both preclinical and clinical studies 
against diseases such as HIV and malaria. In paper I, we use ChAd63 as a booster after a 
DNA replicon prime. 
The rAd vectors described above are replication-deficient due to a deletion of the E1 gene. 
Although this increases the safety of these vectors, it also renders them unable to amplify the 
transgene and thereby possibly less immunogenic. As a strategy to increase immunogenicity 
without compromising safety, a “single cycle” rAd6 vector was generated with an intact E1 
gene, but with a deletion in an Ad capsid gene (100). Upon infection, this virus is able to 
amplify the transgene to a higher degree than replication-deficient rAds, but unable to form 
infectious progeny virions. In rhesus macaques, immunization with single cycle rAd6 
induced enhanced antigen-specific immune responses compared to replication-deficient rAd6 
(101). 
1.3.2 DNA vaccines 
In the early 1990s, it was demonstrated for the first time that DNA plasmids encoding antigen 
derived from a pathogen could induce antigen-specific antibody and T cell responses (102–
104). Since then, DNA vaccines have been tested extensively in preclinical and clinical 
studies for various diseases including HIV, hepatitis C and malaria (105). Three DNA 
vaccines have been licensed for veterinary use: a West Nile virus vaccine for horses, an 
infectious hematopoietic necrosis virus vaccine for salmon, and a therapeutic melanoma 
vaccine for dogs, thus demonstrating that DNA vaccines can elicit protective immunity, also 
in larger animals. 
DNA vaccines have several advantages. They are relatively simple and quick to manufacture 
and are stable at room temperature, which makes the requirement for a cold chain less crucial 
than for many other vaccine platforms. Also, antivector immune responses are not induced, 
thus allowing DNA vaccines to be administered several times without compromising immune 
responses. Since DNA vaccines do not contain any infectious components, they are 
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associated with a high safety profile. Theoretical concerns with DNA vaccines, however, 
include the risk of integration into the host genome and induction of anti-DNA antibodies that 
could lead to autoimmune disease (106). 
DNA vaccines are bacterial plasmids that carry the gene(s) encoding the antigen(s) of interest 
under control of a eukaryotic promoter. The modes of action of DNA vaccine-induced 
immune responses are not completely understood. After delivery into muscle or dermis, DNA 
vaccines are taken up by host cells that then produce the antigen(s), process it and present it 
on MHC class I molecules. In the case of intramuscular (i.m.) delivery, it is likely that 
myocytes as well as APCs such as DCs are transfected (107, 108). The dermis is rich in 
APCs including DCs and Langerhans cells, and it is likely that APCs are also directly 
transfected during intradermal (i.d.) delivery of DNA vaccines. In addition, APCs are 
constantly sampling the environment, and may through endocytosis take up antigen that has 
been secreted or released due to apoptosis. These antigens are then presented on MHC class 
II molecules, or on MHC class I molecules through cross-presentation. APCs will then travel 
to draining lymph nodes and activate antigen-specific B cells, CD4+ and CD8+ T cells. 
Since the DNA plasmid used in DNA vaccines is bacterial in origin, it stimulates innate 
immune responses through PRRs that contribute to its ability to stimulate adaptive immune 
responses. The presence of CpG motifs leads to signaling through TLR9 in endosomes and 
induction of type I IFNs, although this signaling pathway does not appear to be crucial for 
induction of immune responses by DNA vaccines (109–111). Instead, the immunostimulatory 
properties of DNA vaccines leading to induction of type I IFNs and adaptive immunity are 
dependent on cytosolic DNA-sensing pathways (23, 112). 
DNA vaccines have been shown to induce robust B and T cell responses in multiple 
preclinical studies. In humans, DNA vaccines have been demonstrated to be safe and 
tolerated in thousands of volunteers; however, immune responses have generally been low 
and disappointing. Therefore, attempts have been made in increasing the immunogenicity of 
DNA vaccines using a variety of approaches, such as vector optimization. For example, 
alphavirus replicons can be used to increase the immunostimulatory properties of the vector 
backbone. This approach will be described in section 1.4. 
1.3.2.1 Delivery with in vivo electroporation (EP) 
The development of improved delivery methods has resulted in significant improvement of 
the efficacy of DNA vaccines. One such approach that has received much attention within the 
DNA vaccine field is in vivo electroporation (EP). EP involves the application of short 
electrical pulses, the duration of which are in the milliseconds time scale, that form an 
electrical field within the tissue and induce transient and reversible permeabilization of the 
cell membrane. When EP is applied to the tissue immediately after injection of the DNA 
vaccine, it allows for increased cellular uptake of the DNA vaccine, which is then trapped in 
the cells after cells have resealed their membranes, a process that occurs in the seconds to 
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minutes time scale. In addition to increased transfection rates, EP causes local inflammation 
and recruitment of APCs to the site of injection (113, 114). 
Much of the earliest work on in vivo EP for delivery of DNA vaccines focused on i.m. 
delivery; however, more recently there has been a shift towards i.d. delivery. Vaccination in 
the skin has several advantages. First, the skin is an immunocompetent organ, populated with 
various immune cells, including many Langerhans cells and dermal DCs (115). Also, i.d. EP 
is less invasive, as the needles only penetrate 2 mm into the skin, compared to 20 mm for i.m. 
EP (116, 117). I.d. EP is much less painful than i.m. EP, and any residual pain can be 
controlled by a simple application of topical anesthetics (118, 119). Both i.m. and i.d. EP 
have been shown to augment immune responses to DNA vaccines in both smaller animals 
such as mice as well as larger animals such as nonhuman primates (96, 120–122). The 
delivery of a plasmid encoding growth hormone-releasing hormone with EP has been 
licensed in Australia for use in swine (105). In humans, safety and tolerability of EP have 
been demonstrated in clinical trials (123–126). 
1.3.3 Adjuvants 
The term “adjuvant” stems from the latin adjuvare, meaning “to help”, and is defined as 
compounds that enhance adaptive immune responses against a co-administered antigen. The 
earliest developed vaccines did not require co-administration with an adjuvant, as they were 
based on live attenuated viruses that due to their origin possess intrinsic immune-potentiating 
properties. This approach is, however, associated with a too high safety risk for vaccines 
against some pathogens due to the risk of reversion to a pathogenic variant. Also, it may be 
preferable to target immune responses against specific antigens rather than the entire 
pathogen. In these cases, vaccination with purified subunit antigen is a more favorable 
approach. Protein antigens are in themselves not very immunogenic as they are highly 
purified and do not stimulate innate immunity. They therefore often require administration 
with an adjuvant to induce antigen-specific immune responses. The use of adjuvants has the 
additional benefit that they can decrease the antigen dose required, thereby lowering 
production costs. 
Adjuvants have been used in vaccines for almost a century, yet very few adjuvants are 
licensed for use in humans. This is largely because there has been a lack of comprehension of 
the mechanisms of action of adjuvants and efficacious vaccines. Currently licensed adjuvants 
include alum (aluminium salts), oil-in-water emulsions (MF59, AS03 and AF03), virosomes 
and AS04 (monophosphoryl lipid A (MPL) with alum) (127, 128). Recently, there has been 
an increased understanding of innate immunity and PRRs, and it has become apparent that 
one of the most successful licensed vaccines, the live attenuated yellow fever vaccine, 
stimulates DCs through multiple PRRs and induces type I IFNs (59, 129, 130). This has led 
to a rise in development of novel adjuvants designed to stimulate innate immunity, and in 
particular TLRs. Several different TLR ligands have been tested as adjuvants in humans, and 
recently the TLR4 ligand MPL, a non-toxic derivative of lipopolysaccharide (LPS), was 
licensed in Europe and the USA for use in a human papillomavirus vaccine (127). 
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Several chemically synthesized TLR4 agonists are being developed that are more receptor-
specific with less side effects than MPL, which is manufactured by isolation from a gram-
negative bacterium. For example, Glucopyranosyl Lipid Adjuvant (GLA) has been 
demonstrated to be more potent than MPL in stimulating innate immune responses (131). 
GLA promotes humoral and cellular immune responses towards co-administered protein 
antigen derived from influenza or HIV in preclinical models and is currently being evaluated 
in clinical trials (128, 132–135). 
Other PRR ligands are also being assessed as potential adjuvants. For example, the bacterial 
molecule flagellin binds to TLR5 and NLRC4 and is being evaluated for use in an influenza 
vaccine (136–140). Flagellin has also been inserted into viral vectors based on alphavirus, 
adenovirus, paramyxovirus or vesicular stomatitis virus, resulting in enhanced cytokine 
expression by DCs and immune responses to co-administered antigen (141–145). 
Consistently, agonists of different TLRs can synergize in induction of immune responses 
(146–150). For example, it was demonstrated in mice that synthetic nanoparticles containing 
antigen together with TLR4 and TLR7 agonists induces synergistic increases in antigen-
specific neutralizing antibodies compared to particles containing the antigen with only one of 
the TLR ligands (148). 
1.3.4 Heterologous prime-boost vaccination 
Multiple immunizations are often required for a vaccine to be successful. In currently 
licensed vaccines such as the tetanus-diphteria or hepatitis B vaccines, the same vaccine is 
given multiple times in homologous prime-boost vaccination. It has been demonstrated that 
different types of vaccines that contain the same antigen can be combined into heterologous 
prime-boost regimens, and that this often results in antigen-specific immune responses that 
are much stronger than those obtained by homologous prime-boost immunization. This 
approach also circumvents potential problems with antivector immunity that could build up 
by repeatedly immunizing with the same vector. Weakly immunogenic vaccine modalities 
such as DNA vaccines are often used for priming specific responses that are greatly expanded 
by more complex modalities such as virus vectors. 
Heterologous prime-boost immunization was initially demonstrated in a malaria mouse 
model that showed that an influenza virus vector followed by a vaccinia virus vector boost 
induced protective immunity dependent on CD8+ T cells (151). Reversing the order in which 
the modalities were given failed to induce protection. In another study, it was demonstrated 
that priming with DNA followed by an MVA boost induced cellular immune responses that 
were greater than those obtained by immunizing with only one of the vaccine modalities or 
reversing the order in which they were given (152). Various preclinical and clinical studies 
have been carried out using DNA as a prime followed by a poxvirus or adenovirus boost for 
vaccines against pathogens such as HIV, tuberculosis and malaria (64, 73–76, 96, 153–156). 
The immunological mechanisms for the increased responses observed in heterologous prime-
boost immunization are not well understood, although one explanation may be that this 
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approach helps to focus the immune response on the antigen (72, 157, 158). The DNA prime 
induces a weak yet highly specific response against the antigen of interest. When a greatly 
immunogenic modality such as a virus vector, encoding the same antigen, is given as a boost, 
the immune response to the antigen will have an advantage over induction of responses 
against the vector. This allows for efficient expansion of immune responses focused towards 
the antigen. A high replicative capacity of the booster appears to be important, as 
demonstrated in a recent study in which an LCMV booster with an enhanced replicative 
capacity induced augmented immune responses and improved protective capacity compared 
to an LCMV strain that is more rapidly controlled by the immune system (159). 
Another prime-boost combination that is being assessed is boosting with a recombinant 
protein antigen after priming with a weakly immunogenic vector. Various studies have 
employed DNA vaccines for priming antibody responses that are boosted by protein subunit 
vaccines (160, 161). The most extensive HIV vaccine study using a heterologous protein 
boost was the phase III trial in Thailand (RV144) involving 16,000 individuals. The vaccine 
tested in the trial was composed of four initial administrations of ALVAC followed by two 
boosters with recombinant HIV Env protein and resulted in modest efficacy (77). 
Since viral vectors greatly expand T cell responses, and protein antigens are optimal for 
boosting antibody responses, vaccination regimens containing both of these vaccine 
modalities may be a strategy for induction of both arms of adaptive immunity (83, 134). 
Another way of tailoring immune responses is by altering the interval between prime and 
boost. Although the ideal time interval depends on the vaccine modality, in general responses 
are optimized by administering the booster only after the primary response has contracted 
(99, 162–164). 
1.4 ALPHAVIRUS REPLICONS IN VACCINATION 
The Alphavirus genus belongs to the Togaviridae family and is a group of enveloped viruses 
containing a positive-sense ssRNA genome. Thirty different alphaviruses have been 
identified, including Semliki Forest virus (SFV), Sindbis virus (SIN), Venezuelan equine 
encephalitis virus (VEE) and Chikungunya virus (CHIKV) (165). SFV was first isolated in 
1942 from mosquitoes captured from the Semliki Forest in Uganda. SFV generally does not 
cause disease in humans. In the rare cases where human infection has been observed, SFV 
caused only mild symptoms such as fever, rash and headache. In mice, however, SFV is 
highly virulent and causes encephalitis (166). CHIKV has recently received much attention 
due to its reemergence and spread in Africa, Asia, Europe and the Americas. CHIKV is 
mosquito-borne and causes severe arthralgic disease in humans which in rare cases can be 
fatal (167). Currently, no vaccine is available against CHIKV, although several vaccine 
candidates are in preclinical development and a few in clinical trials (82, 83, 168–171). 
1.4.1 Genome and replication 
The alphavirus genome has a 5’ cap structure and is polyadenylated at the 3’ terminus (Fig. 
2). It is approximately 11.5 kb in length and contains two ORFs. The first ORF comprises the 
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5’ two-thirds of the genome and encodes the four non-structural proteins (nsPs) 1-4. These 
proteins are translated as a polyprotein that self-cleaves into separate proteins, which 
assemble into a replicase complex. The replicase then directs replication and amplification of 
the viral genome in the infected cell cytoplasm. Later in the infection cycle, the replicase 
drives transcription of subgenomic RNA containing the second ORF from a 26S promoter on 
negative-stranded RNA formed during RNA replication. The structural proteins of the virus 
are encoded in the second ORF. These include the capsid protein, which interacts with the 
RNA genome and forms the icosahedral nucleocapsid, and the glycoproteins E3, E2, 6K and 
E1, which are processed into the virion spikes. 
During infection, translation of host mRNA is shut off so that only viral proteins are 
produced by the cell. In cells infected with SFV, this is a result of the cellular stress response, 
leading to phosphorylation of eukaryotic translation initiation factor 2α and the transient 
formation of stress granules (172). Although three viral RNA species are formed during 
infection, only the genome is packaged into progeny virions. This is due to an RNA sequence 
that functions as a packaging signal and is required for packaging into virus particles. The 
packaging signal is located in the genes encoding nsP, and specifically in nsP2 for SFV 
(173). New virions are released from the host cell by budding and can infect new cells by 
attaching to the host cell membrane followed by receptor-mediated endocytosis. 
1.4.2 Alphavirus infection and host response 
Alphaviruses have a broad host range, infecting a wide variety of cell types from both insects 
such as mosquitoes and vertebrates including birds and mammals (165, 174). The primary 
mode of transmission of alphaviruses between vertebrates is by mosquito bites. The receptor 
that alphaviruses utilize for entry into cells is still unknown for most alphaviruses, including 
SFV. After subcutaneous entry, alphaviruses either infect skeletal muscle (e.g. SFV) or 
Langerhans cells directly (e.g. VEE), although it is not entirely clear which cells are infected. 
Virus is subsequently transported to draining lymph nodes, either in infected Langerhans 
cells or DCs, or as free virus. The virus then further replicates in the draining lymph nodes, 
leading to systemic infection (175, 176). 
Alphaviruses are detected by the host through multiple PRRs including the endosomal 
receptors TLR3, TLR7 and TLR8, and the cytoplasmic receptors MDA5 and protein kinase R 
(177–181). The signaling through PRRs leads to induction of a strong type I IFN response, 
nsP1-4 Capsid+spike5’ 3’ + sensegenomic RNA
Replicase
- sense
antigenomic RNA3’ 5’
26S promoter
+ sense
subgenomic RNA5’ 3’
Structural proteins
Figure 2. Replication of the alphavirus 
genome. The alphavirus replicase is 
translated from genomic RNA. The replicase 
then drives genome replication and 
transcription of subgenomic RNA, from 
which the structural proteins are translated. 
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apoptosis and thereby cross-priming of antigen epitopes on MHC class I molecules (182–
185). Infection with alphaviruses results in induction of both cellular and humoral immune 
responses. 
1.4.3 Alphavirus replicons 
Expression vectors have been generated from alphaviruses by replacing the genes encoding 
the alphavirus structural genes by a transgene encoding a gene of interest. Due to the 
presence of the genes encoding the alphavirus nsPs, the resulting RNA is self-replicating and 
is termed a replicon (171). Since the genes encoding the structural proteins are deleted, no 
new virions are formed after a replicon is introduced into a host cell. Alphavirus replicons 
have been constructed based on SFV (186), SIN (187) and VEE (188). These can be 
delivered either packaged into viral particles (VREP), or as naked DNA (DREP) or RNA 
(RREP). In this thesis, VREP and DREP based on SFV were studied. 
For packaging of VREP, the replicon RNA is transfected into a cell line together with helper 
vectors that supply the alphavirus structural proteins in trans (Fig. 3). To minimize the risk of 
recombination that could lead to the formation of replication-competent viruses, the spike and 
capsid genes are placed on two separate helper constructs in the so-called ‘split-helper’ 
system (189). After transfection, helper RNAs are replicated by the viral replicase from the 
26S promoter. Due to the lack of packaging signal, they are not packaged into the VREP 
particles. Thus, VREP particles contain only the replicon RNA, but are otherwise 
indistinguishable from WT viral particles. The RNA in VREP particles is identical to RREP, 
and is produced by in vitro transcription of a recombinant alphavirus cDNA with an SP6 or 
T7 promoter (SP6 in the constructs used in this thesis). DREP is obtained by swapping this 
promoter with a eukaryotic promoter such as the cytomegalovirus promoter. 
When the RNA of VREP or RREP enters the cytoplasm of the host cell through infection or 
transfection, the viral replicase is translated (Fig. 4). Like in natural infection with 
alphaviruses, the replicase drives replication and amplification of replicon RNA as well as 
Capsid Spike
nsP1-4 Foreign gene
26S promoter
Packaging signal
RREP
‘Split helper’ RNAs
VREP
Figure 3. Packaging of VREP. Replicon RNA (RREP) and helper RNAs encoding the alphavirus structural 
proteins are co-electroporated into cells, resulting in the production of viral particles containing RREP (VREP). 
Since VREP does not contain the genes encoding the structural proteins, infection with VREP does not result in 
production of progeny virus. 
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transcription of subgenomic RNA, from which the antigen of interest can be translated. When 
cells are transfected with DREP, the DNA is first transported into the cell nucleus, where it is 
transcribed into replicon RNA that is then transported to the cytoplasm. The replicon RNA 
transcribed from DREP is identical to the RNA of VREP and RREP, and thus the 
amplification cycles are identical for the three platforms once RNA has been transcribed from 
DREP and has been transported to the cytoplasm. 
nsP1-4 Foreign gene
26S promoterRREP nsP1-4 Foreign gene
26S promoterCMV promoter
DREP
VREP
transfection
infection
transfection
transcription
nuclear
export
translation of
alphavirus replicase
negative strand synthesis
+ sense RNA
+ sense RNA
- sense RNA
genome
replication transcription of
subgenomic RNA Foreign antigen
+ sense RNA
DNA
translation of
subgenomic RNA
+ sense RNA
+ sense subgenomic RNA
Figure 4. Cellular processing of alphavirus replicons. Alphavirus replicons can be delivered packaged into 
viral particles (VREP), or as naked RNA (RREP) or DNA (DREP). After transfection, DREP is transcribed into 
RNA that is identical to RREP and the RNA of VREP. From this RNA, the alphavirus replicase is translated, which 
then drives amplification of replicon RNA as well as transcription of subgenomic RNA encoding an antigen of 
interest. From this RNA, large amounts of the foreign antigen is produced. CMV, cytomegalovirus. 
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1.4.3.1 Translational enhancer 
The 5’ end of the capsid gene of SFV and SIN, but not VEE and CHIKV, contains a 
translational enhancer (190–192). In SFV, the enhancer is present in the RNA encoding the 
first 34 amino acids of the capsid. Placing these residues upstream of the transgene encoding 
the antigen of interest in the replicon RNA increases transgene expression eight-fold (192). In 
order to obtain translation of antigen that is not attached to this capsid fragment, a 17 amino 
acid sequence of the 2A autoprotease of foot-and-mouth disease virus is inserted in frame 
directly after the capsid translational enhancer. During translation, the 2A nascent peptide 
modifies the activity of the ribosome to carry out ribosomal ‘skipping’ (193, 194). In this 
process, the ester linkage between tRNA and the C-terminal amino acid of 2A is hydrolyzed, 
resulting in release of the nascent capsid-2A peptide from the ribosome. The ribosome then 
continues translating the downstream sequence, resulting in production of a peptide that is not 
attached to the capsid-2A residues. 
1.4.4 Applications in vaccines 
The intrinsic immunostimulatory properties of alphavirus replicons as well as their ability to 
stimulate cellular and humoral immune responses make them ideal for use as vaccines. The 
amplification cycle of replicon RNA in host cells mimics viral infection with production of 
ssRNA and dsRNA intermediates that stimulate multiple PRRs as described above, leading to 
induction of type I IFNs, apoptosis and thereby promotion of cross-priming (182–185). 
DREP, being a DNA vaccine, additionally stimulates TLR9 and cytosolic DNA sensors (23, 
109–112). The resulting type I IFN response has a dual effect, since type I IFNs on the one 
hand promote immune responses, but on the other hand can suppress expression of the 
transgene and thereby actually limit antigen-specific responses (96, 179). 
Additional features that make alphavirus replicons attractive vaccine platforms include their 
broad host range and high levels of transgene expression. Also, antivector immunity is not 
prevalent, and although antibodies directed at the vector are induced after immunization, they 
do not interfere with the immune response to the vectored immunogen in cases where the 
replicon is administered multiple times (188, 195–197). Induction of apoptosis by the 
replicon reduces the theoretical risk of integration of the viral genome into the host genome. 
Since the RNA of RREP and VREP replicates in the cytoplasm, this further eliminates the 
risk of integration. Replicons are associated with a high safety profile with a minimal risk of 
causing disease. Moreover, the replicons used in this thesis were based on SFV, which is 
associated with only mild human disease. 
1.4.4.1 Viral replicon (VREP) 
The VREP vector has been shown to induce robust antigen-specific immune responses of 
both the cellular and humoral arms and has been tested in both preclinical and clinical studies 
(171). The majority of vaccine studies using alphavirus replicons have focused on the VREP 
platform, and thus most data on alphavirus replicon vaccines stems from these studies. VREP 
has been tested in multiple animal models including mice and non-human primates for 
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diseases such as HIV, influenza and dengue fever (98, 195, 197–199). In paper II, we 
characterize the kinetics and phenotype of the antigen-specific CD8+ T cell responses induced 
by the VREP vector. VREP has also been tested together with other vectors in heterologous 
prime-boost studies. For example, VREP was shown to prime HIV-specific T cells that are 
efficiently boosted using an MVA vector (200). In humans, VREP has been demonstrated to 
be safe, but immunological data is still limited (171). 
Due to its strong stimulation of innate immunity, VREP can also be used as an adjuvant. 
When co-administered with protein antigen, VREP potentiates antigen-specific cellular and 
humoral immune responses (201–203). The adjuvant effect is dependent on type I IFN 
signaling (143, 201). In paper IV, we show that the adjuvant effect of VREP can be further 
enhanced by incorporation of the TLR5 and NLRC4 agonist flagellin. 
1.4.4.2 DNA replicon (DREP) 
As described above, the development of DNA vaccines has been hampered by low 
immunogenicity in humans and thus the requirement of high doses (105, 119).  We and 
others have demonstrated the use of the DREP vector as a strategy to increase the 
immunogenicity of DNA vaccines (96, 179, 204–208). This vector carries intrinsic 
immunostimulatory properties, as described above, and thereby requires lower doses while 
still inducing stronger antigen-specific cellular immune responses compared to conventional 
plasmid DNA vectors. The use of EP for delivery of DREP further increases antigen-specific 
immune responses and allows for an additional dose-sparing effect (96). 
DREP can also be given as a prime prior to a heterologous boost that further expands T cell 
responses. For example, we show in paper I in mice and rhesus macaques that DREP is 
superior to conventional plasmid DNA in priming HIV-specific T cells that are boosted by an 
MVA or ChAd63 vector encoding the same immunogen (96). In paper III we further 
explore the prime-boost regimen by boosting with both MVA and protein antigen in GLA 
adjuvant. 
DREP is furthermore being evaluated as a vaccine candidate for CHIKV. In this case, DREP 
contains the whole CHIKV genome but lacks the capsid-encoding sequences. It thus only 
expresses the envelope membrane proteins of CHIKV and is unable to form infectious virions 
upon transfection into cells (83). CHIKV-specific T cell and antibody responses primed by 
DREP are boosted to high levels by protein and MVA boosts, and confer protection against 
CHIKV in a murine model. 
1.4.4.3 RNA replicon (RREP) 
Alphavirus replicons can also be delivered as a naked RNA vector, or RREP. This approach 
has the advantage that the theoretical risk of genome integration is eliminated. Also, gene 
expression is transient and does not persist. Therapy with RNA is not classified as gene 
therapy by regulatory authorities, allowing for a more rapid progress of RNA vaccines into 
clinical trials. The naked RNA vaccine platform has not been studied as extensively as viral 
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vectors or DNA vaccines due to initial concerns about instability of RNA and difficulties 
with large-scale manufacturing. With recent development in manufacturing technology and 
delivery methods, these are no longer viewed as hurdles, which has given the RNA vaccine 
platform more attention as an alternative to other approaches. Also, RREP appears to be 
rather resistant to degradation, possibly due to its secondary structure. 
I.m. injection with RREP expressing influenza antigens into mice results in strong humoral 
and cellular immune responses that are protective against challenge (209, 210). These 
responses are further augmented by improved delivery methods such as EP or formulation in 
lipid nanoparticles (117, 211–213). RREP formulated in lipid nanoparticles was recently 
demonstrated to induce potent HIV-specific cellular and humoral immune responses in rhesus 
macaques (213). 
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2 AIMS OF THIS THESIS 
Detailed understanding of immune responses induced by different vaccine platforms is 
important for rational vaccine design. The aim of this thesis was to evaluate the use of 
alphavirus replicons as a vaccine platform with the intent to use this knowledge to optimize 
this platform for future use in the clinic. Specifically, the aims were defined as follows: 
• To further enhance the immunogenicity of the alphavirus replicon by improved delivery 
methods or incorporation of additional PRR stimulants. 
• To evaluate the use of DREP as a prime in heterologous prime-boost regimens prior to a 
viral vector or protein boost. 
• To characterize memory T cell populations induced by alphavirus replicons, and assess 
how these are affected by varying factors such as timing and dose. 
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3 RESULTS AND DISCUSSION 
In this thesis, we studied antigen-specific CD8+ T cell and antibody responses induced by 
alphavirus replicons using a murine model, with the purpose of evaluating this platform for 
use in future vaccines. VREP and DREP constructs used in this thesis were based on SFV. 
We used HIV antigens that are being assessed in clinical trials in papers I and III and model 
antigens in papers II and IV. Specifically, in paper I we used HIVconsv, an HIV 
immunogen designed to encode 14 of the most conserved regions of the proteome of the four 
major HIV clades A, B, C and D. We assessed T cell responses against a single 
immunodominant epitope inserted for the purpose of preclinical evaluation. In paper III, we 
used Env and a Gag-Pol-Nef fusion protein from HIV clade C. Chicken ovalbumin was used 
as a model antigen in paper II, as it has a well-characterized and strong CD8+ T cell epitope. 
The model antigen β-galactosidase was used in paper IV. 
Antigen-specific CD8+ T cell responses were enumerated by IFN-γ enzyme-linked 
immunosorbent spot (ELISpot), a sensitive assay that detects cells that secrete IFN-γ in 
response to ex vivo peptide stimulation. To assess functionality of CD8+ T cells, cells were 
stained with the intracellular cytokine staining (ICS) method to detect production of IFN-γ, 
IL-2 and TNF-α in response to peptide stimulation. In paper III, we additionally assessed 
cytotoxic function by detecting mobilization of degranulation marker CD107a in the ICS 
assay. In paper II, we characterized CD8+ T cell responses with pentamer staining, a method 
that utilizes a complex of five MHC-peptide molecules to detect CD8+ T cells with 
complementary T cell receptors. In the pentamer assay, we stained for surface markers 
including CD127, CD62L, CD43 and CD27 to characterize the phenotypes of memory T 
cells. 
Antigen-specific antibody levels were assessed with enzyme-linked immunosorbent assay 
(ELISA), an assay that measures the amount of antibodies that can bind to the antigen, but 
not their ability to neutralize. Total antigen-specific IgG responses were assessed, as well as 
IgG1 and IgG2a isotype responses, as a measure for Th2- and Th1-type responses, 
respectively. 
3.1 IMMUNE RESPONSES INDUCED BY ALPHAVIRUS REPLICONS 
3.1.1 CD8+ T cell responses 
3.1.1.1 Dose-response 
Delivery of DNA vaccines by in vivo EP greatly enhances antigen-specific immune responses 
(116, 119–122). This delivery method had prior to this thesis, however, not been evaluated 
for delivery of DREP. DREP induces multiple inflammatory signals, and therefore it was not 
obvious whether this would overshadow the inflammation and enhancement of immune 
responses potentiated by EP. We tested this in paper I by immunizing mice with various 
doses of DREP or conventional plasmid DNA, delivered using either the i.m., i.d. or i.d. EP 
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immunization routes. Using IFN-γ ELISpot, we compared the magnitudes of antigen-specific 
CD8+ T cell responses. 
With all immunization routes, substantially lower doses of DREP were required to induce 
responses equivalent in magnitude as conventional DNA. Delivering DREP with EP resulted 
in significantly increased responses compared to immunization via the i.m. or i.d. routes 
without EP. Responses induced by delivery of DREP with EP reached a higher level 
compared to the responses obtained without EP and were dose-dependent up to 2 µg, where 
the dose-response curve reached a plateau. In addition to obtaining stronger responses, the 
use of EP allowed for dose sparing. With the EP delivery route, the dose of DREP could be 
reduced 125 times to obtain the same magnitude of response induced without EP. 
Furthermore, a dose of DREP that was 625-fold lower than conventional DNA induced 
equivalent responses. Doses typically used in DNA vaccine studies in mice range from 25-
100 µg. For example, an optimized non-replicon DNA vaccine given with i.m. EP required 
35 µg for induction of optimal T cell responses (214). Thus, the results from paper I suggest 
that the dose can be substantially reduced by the use of DREP rather than conventional DNA. 
We also showed in papers I and III that the responses induced by a single immunization 
with an optimal or suboptimal dose of DREP are boosted to a higher level by two 
homologous boosts. Similarly, a study in rhesus macaques showed that multiple 
immunizations with a conventional DNA vaccine results in increased responses, whereas the 
responses induced by rAd5 were not increased after homologous boosts, probably due to 
induction of antivector immunity (215). T cells induced by the DNA vaccine were 
characterized by greater replicative capacity and increased polyfunctionality compared to 
responses induced by rAd5. In paper III, we showed that the proportions of multifunctional 
cells induced by DREP are greater than those induced by conventional DNA. 
3.1.1.2 Kinetics 
In paper II, we characterized the kinetics of antigen-specific CD8+ T cell responses induced 
by the VREP and DREP vectors. This knowledge is important for understanding memory T 
cell formation and can be used to optimize the time interval in prime-boost vaccination. We 
immunized mice with VREP or DREP constructs and followed the development of antigen-
specific CD8+ T cell responses after a single immunization using IFN-γ ELISpot. We 
observed that responses induced by VREP or DREP had a sharp peak, followed by a rapid 
contraction. 
For mice immunized with VREP, the responses peaked on days 7-8 and had contracted by 
day 21. Following immunization with DREP, responses peaked after 10 days and had 
contracted substantially 2 weeks after immunization. The pattern of the CD8+ T cell 
responses induced by VREP and DREP are similar to those induced by the live attenuated 
yellow fever virus and smallpox vaccines, two highly successful human vaccines. With these 
vaccines, responses peak rapidly within 2 weeks and have contracted by 4 weeks after 
vaccination (216, 217). In contrast, T cell responses induced by rAd5, which was used in the 
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STEP trial, have a later peak, between days 15 and 25, and do not rapidly contract but rather 
remain at a high level (85, 92, 99, 218). 
When a second homologous replicon immunization was given after 3 weeks, responses 
peaked to higher levels and more rapidly than after the primary immunization. Responses 
peaked already 6 days after a second immunization with VREP and 8 days after 
immunization with DREP. After contraction, the number of CD8+ T cells was maintained at a 
higher level than after the primary response, in accordance with previous knowledge that 
contraction after an anamnestic response is less pronounced than after the primary response 
(219–222). 
We also tested different time intervals between prime and boost and observed that it was 
necessary to wait until the CD8+ T cell response had contracted before administering a 
booster. Administering a booster during the peak response resulted in a memory response of 
lower magnitude compared to that obtained when the booster was given 3 weeks or longer 
after the prime. This was likely due to the necessity of formation of a sufficient memory cell 
frequency before the response can be boosted. Accordingly, we observed that less than half of 
the antigen-specific CD8+ T cells had developed a memory phenotype during the peak 
response, whereas this frequency was close to 90% after contraction. Previous studies have 
also shown that waiting a longer time between prime and boost enhances the secondary 
effector response (47, 99, 162, 164). The interval observed with alphavirus replicons was, 
however, shorter than for rAd vectors, for which an interval of 8 or more weeks between 
prime and boost is optimal (99, 162). In an influenza vaccine trial, boosting with an 
inactivated influenza vaccine gave an optimal response when waiting at least 12 weeks after a 
DNA prime (164). 
3.1.1.3 Memory phenotype 
In paper II, we characterized the memory phenotype of CD8+ T cell responses induced by 
VREP and DREP. We immunized mice and characterized antigen-specific CD8+ T cell 
responses with tetramer staining as well as memory marker staining. Tem and Tcm 
subpopulations were identified based on CD127/CD62L staining (46–49, 223). In addition, 
CD27/CD43 staining was used to identify CD27+ CD43- memory T cells known to have a 
high recall capacity (56–58). 
A single immunization with either VREP or DREP induced a memory CD8+ T cell 
population characterized by both Tem and Tcm. The memory population that developed after 
a homologous boost consisted of a higher Tem:Tcm ratio, in accordance with previous 
observations that repeated antigen exposure promotes generation and maintenance of Tem, 
and that secondary memory T cells are slower to acquire a Tcm phenotype (222, 224). 
Immunization with increasing doses of VREP resulted in an enhancement of Tem formation, 
whereas the proportions of Tcm decreased with higher doses. These observations were in line 
with a model proposing that increased signal strength favors formation of Tem rather than 
Tcm (46). Vectors based on other nonpersistent viruses such as vaccinia virus also induce 
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both Tcm and Tem (82). In contrast, low-level persisting viruses such as rAd and CMV 
induce predominantly Tem and are poor inducers of Tcm (85, 218, 225). 
Analyzing the CD27/CD43 phenotype, we saw that the majority of antigen-specific CD8+ T 
cells had a CD27+ CD43+ phenotype during the acute response after a single immunization 
with DREP or VREP. Over time, the proportion of this population decreased, while the 
CD27+ CD43- cell subpopulation increased, in accordance with previous observations with a 
Sendai virus model (56). After a second immunization, the proportion of CD27+ CD43+ cells 
further decreased. In contrast to what we observed with the Tem and Tcm phenotypes, the 
proportions of CD27+ CD43+ and CD27+ CD43- cells did not differ by varying the dose of 
VREP. 
As described in the introduction, the type of memory T cells that are optimal for pathogen 
control will depend on the specific pathogen. Tem are important for control of infections that 
replicate in the periphery including HIV (38, 55), malaria (226, 227) and vaccinia virus (52), 
whereas Tcm play an important role against systemic LCMV infection, which replicates in 
lymphoid organs (52–54), and against a P18 tumor challenge (90). Memory T cells with a 
CD27+ CD43- phenotype have been implicated as important for control of Sendai virus, 
hepatitis C virus and LCMV infection, although this phenotype has not been as extensively 
studied as the Tem and Tcm subpopulations (56–58). The characterization of memory T cell 
subpopulations induced by replicons, and knowledge of how these can be altered by varying 
factors such as dose, can be used to tailor vaccination regimens to induce responses that are 
optimal for control and/or clearance of a specific pathogen and are therefore important for 
design of future clinical trials. 
3.1.2 Antibody responses 
The rationale for the development of DNA vaccines was to induce cellular immunity, and 
‘first-generation’ DNA vaccines were generally poor inducers of antibody responses. More 
recently, however, optimized DNA vaccines have demonstrated the ability to induce antibody 
responses after multiple immunizations (105, 214). DREP has also been shown to induce 
modest levels of antibodies (204, 208). In paper III, we assessed antibody responses induced 
by DREP delivered by i.d. EP. We immunized mice with one, two or three homologous 
administrations of either a high (10 µg) or low (0.2 µg) dose of DREP. Three weeks after the 
last immunization, we analyzed total antigen-specific IgG responses. A low but clearly 
detectable response was induced in all groups except in the group given the low dose once. A 
single immunization of 10 µg CHIKV DREP delivered by i.d. EP was also recently shown to 
induce antibodies that protected 4 of 5 mice from a CHIKV challenge (83). Administering 
CHIKV DREP twice resulted in antibodies that were boosted to a higher level and protected 
all mice from CHIKV challenge. 
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3.2 ALPHAVIRUS REPLICONS IN HETEROLOGOUS PRIME-BOOST 
REGIMENS 
DNA vaccines have been shown to be excellent priming agents in heterologous prime-boost 
vaccine regimens (72–76, 105, 153–155). Results from clinical trials have, however, shown 
that repeated immunization with high doses of DNA is required for induction of long-lived 
immune responses. Thus, more work is needed for the DNA vaccine platform to be viable for 
use in human vaccines. Since we showed in paper I that electroporated DREP is superior to 
conventional DNA vaccines in inducing antigen-specific immune responses, we assessed the 
outcome of administering DREP by i.d. EP as a prime prior to a heterologous boost. We 
compared DREP with conventional DNA and investigated the effect of varying dose and 
number of DREP primes. 
3.2.1 DREP compared to conventional DNA vaccine as a prime 
In paper I, we compared the ability of DREP and conventional DNA to prime antigen-
specific CD8+ T cell responses prior to a heterologous virus vector boost. We immunized 
mice once with DREP or conventional DNA followed by a boost with either MVA or 
ChAd63. We selected two priming doses for both DREP and conventional DNA: one dose 
that in the dose-titration experiment described above induced a maximal response (2.5 µg of 
DREP and 25 µg of conventional DNA), and one dose that induced intermediate T cell 
frequencies (0.05 µg of DREP and 2.5 µg of conventional DNA). Responses primed by 
DREP were superior in magnitude to those primed by conventional DNA. This was evident 
at both 1 and 5 weeks post-boost. MVA and ChAd63 appeared similar as boosting agents, 
both in terms of frequencies of antigen-specific CD8+ T cells and expression of cytokines. 
The DREP-MVA regimen was also assessed in a CHIKV vaccine study. Similar to this study, 
CHIKV DREP or MVA by themselves induced only modest T cell responses, but by 
administering MVA after a single prime with DREP, T cells were expanded to extremely 
high levels (83). The MVA used in the CHIKV study had an enhanced immunogenicity due 
to deletion of immunomodulatory genes (82). In paper II we show that the MVA boost 
mainly favored expansion of Tem cells when given after a CHIKV DREP prime, similarly to 
previous observations with MVA by itself of given after a conventional DNA vaccine prime 
(82, 228–230). rAd also induces T cell responses predominantly of the Tem phenotype (85, 
218, 225). 
We also compared DREP and conventional DNA in their abilities to prime T cell responses 
in rhesus macaques. We primed animals three times with either 400 µg of DREP or 4 mg of 
conventional DNA; i.e. we used a 10-fold lower mass, equivalent to a 20-fold lower molar 
dose, of DREP than conventional DNA. Animals were boosted sequentially with MVA and 
ChAd63 vaccines. Despite the lower dose of DREP given, frequencies of antigen-specific 
CD8+ T cells induced by DREP or conventional plasmid DNA were equivalent, as 
determined by IFN-γ ELISpot using peptide pools as stimuli. Analyzing the responses 
induced by the different peptide pools, we observed that the breadth of responses were also 
similar. Macaques primed with DREP consistently displayed higher frequencies of 
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multifunctional CD4+ and CD8+ T cells than animals primed with conventional DNA, 
although these differences were not statistically significant. 
Multifunctional T cells play a central role for protection against viral disease (43, 44). In 
another study in rhesus macaques, we assessed the potential of using alphavirus replicons as a 
boost. We boosted rhesus macaques with VREP encoding the HIVconsv immunogen 
following immunization with DNA, synthetic long peptides, MVA and ChAd63 (98). The 
results from this study indicated that polyfunctionality of antigen-specific T cells increased 
after administration of VREP (Fig. 5). Other studies have also indicated increased 
polyfunctionality with the use of mixed modality vaccine regimens. For example, in a 
hepatitis C vaccine study, immunizing mice with a DNA-MVA vaccine regimen resulted in 
broader and more polyfunctional T cell responses compared to an MVA-MVA regimen 
(228). It would be relevant to address broadness of responses induced by DREP more 
extensively in future studies, as immune responses against subdominant epitopes will be 
important for future vaccines against highly variable pathogens such as HIV and hepatitis C 
virus. 
3.2.2 Effect of varying the number of primes with DREP 
Preclinical and clinical prime-boost studies most often utilize multiple administrations of 
DNA due to its weak immunogenicity. As we had demonstrated higher immunogenicity of 
DREP than conventional DNA vaccines in paper I, and in particular when delivered by i.d. 
EP, we asked in paper III what the effect would be of varying the number of DREP primes 
prior to a heterologous boost, and whether there would be a difference by priming multiple 
times with different doses. We therefore primed mice either one or three times with either 10 
µg or 0.2 µg of DREP encoding antigens from HIV clade C. Mice were then boosted with 
one of the following: 1) MVA encoding the same antigens, 2) gp140 protein in GLA aqueous 
formulation (GLA-AF) adjuvant, 3) MVA followed by a second boost with protein/adjuvant, 
or 4) MVA and protein/adjuvant simultaneously. The rationale was that MVA would boost T 
cells while protein/adjuvant would boost antibodies. As a shortened vaccine regimen would 
the generation of responses with desirable proliferative and
polyfunctional features.
In the pathogenic SIVmac239 challenge model, it is well
established that CD81 T-cell responses to the Mamu-A!01-restric-
ted SIV Gag-derived epitope CM9 are protective; however, this
effect is independent of response magnitude in the periphery
[32–34]. More recently, the early mobilization of public CM9-
specific CD81 T-cell clonotypes, defined as those that express
identical TCR at the amino acid level and exhibit inter-individual
sharing, has been identified as a molecular signature of protection
[35]. We therefore examined TCR usage within CD81 T-cell
populations specific for the C-terminal CM9 epitope in the
HIVconsv immunogen using a template-switch anchored RT-PCR
that amplifies all expressed TRB gene products without bias; in
addition, we conducted a detailed phenotypic analysis of these
populations during the polychromatic flow cytometric sorting
process. Cognate CD81 T cells that bound the CM9/Mamu-A!01
tetrameric complex were phenotypically heterogeneous. Thus, the
majority of CD31CD4–CD81CD951tetramer1 T cells from Octavia
were CD281CD45RAdim following both the DDDAM regimen (day
287) and the SSCMV boosts (day 615). In contrast, the corre-
sponding CD31CD4!CD81CD951tetramer1 T cells from One were
predominantly CD28–CD45RAdim at day 287, thereby indicating a
greater degree of differentiation, and exhibited a mixture of
CD28–CD45RAdim and CD281CD45RAdim phenotypes at day 615
(Fig. 4A). Similar to One, the CD31CD4-CD81CD951tetramer1
T cells in Ozone displayed phenotypic heterogeneity at both time
points, but with a predominance of CD281CD45RAdim cells at day
287 (data not shown). There were also substantial differences with
respect to TCR usage within the CD31CD4!CD81CD951tetramer1
T-cell populations. Thus, while a highly skewed oligoclonal reper-
toire was mobilized in all cases, public CM9-specific CD81 T-cell
clonotypes were identified only in Octavia and Ozone (Fig. 4B and
data not shown). In Octavia, the initially dominant clonotypes were
maintained at day 615, albeit with an altered hierarchical structure;
additional public clonotypes, one of which achieved numerical
dominance, were also recruited during this time (Fig. 4B).
However, with the exception of a single preserved clonotype, a
more dynamic pattern was observed in One. Thus, consistent with
Table 2. Cross-recognition of the most frequent epitope variants reported in the LANL database by T cells induced by the HIV-1 Gag-derived
Mamu-A!01-restricted epitope FSPEVIPMF embedded in the HIVconsv immunogena)
Day ONE OZONE OCTAVIA
f (%) 169 493 526 595 169 493 526 595 169 493 526 595
FSPEVIPMF 79.1 nd 264 800 646 33 0 273 273 nd 326 1233 1233
FNPEVIPMF 9.0 66 495 660 607 0 0 380 306 750 359 526 595
FSPEIIPMF 2.3 88 495 733 686 66 60 313 220 700 379 833 1033
QSPEVIPMF 1.77 77 1419 680 666 nd 0 446 539 nd 400 1259 1153
FNPEIIPMF 1.01 55 0 586 646 nd 0 273 273 687 0 953 966
FSPQVIPMF 0.08 66 363 813 686 nd 54 406 519 nd 333 1253 1133
a) f – frequency of epitope variants in the LANL database. The frequencies of specific T cells are shown as SFU/106 PBMC after subtracting
background reactivity in the absence of peptide. As frozen samples were limiting, some variants were not tested (nd – not done). Day 169 is post-
DDDAM, day 493 is post-DDDAMS, day 526 is post-DDDAMSSC, and day 595 is post-DDDAMSSCMV.
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Figure 3. Proliferative capacity and functional profile of HIVconsv-
elicited CD81 T cells. (A) Isolated PBMC from day 493 were labeled with
CFSE and stimulated with peptides corresponding the conserved
regions of HIV-1 Gag (Pool 1) or mock stimulated with medium alone
(Ø) for 5 days and analyzed for division-based dilution using flow
cytometry. Gates for proliferating CD81 and CD8! cells are shown with
the percentages of CD31 cells for the two populations given above.
(B) PBMC from day 407 (after DDDAM), day 497 (after DDDAMSS) and
day 590 (after DDDAMSSCMV) were stimulated with Pool 1 peptides
and the production of IFN-g, TNF-a and IL-2 by CD81 cells was
determined in a polychromatic intracellular cytokine staining assay.
Pie charts indicate the fractions of Pool 1-specific CD81 cells that
expressed 1 (light grey), 2 (dark grey), or 3 (black) cytokines.
Eur. J. Immunol. 2010. 40: 1973–1984Maximillian Rosario et al.1978
& 2010 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
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Figure 5. Functional profiles of HIVconsv-specific 
CD8+ T cells. Three rhesus macaques were immunized 
with the regimen stated above pie charts. Monkey 
number id is shown to the left of charts. All vaccine 
constructs encoded the HIVconsv immunogen. Cells 
were assayed with ICS for production of IFN-γ, IL-2 and 
TNF-α. The proportion of antigen-specific CD8+ T cells 
producing 3 (black), 2 (dark gray) or 1 of these cytokines 
is illustrated in the pie charts. D, DNA; A, rAd5; M, MVA; 
S, synthetic long peptides; C, ChAd63; V, VREP. Figure 
modified from (98). 
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be favorable in a clinical setting since it may increase compliance, we tested whether we 
could administer the two boosts simultaneously without compromising immune responses. 
A single prime with a low dose of DREP was sufficient for priming of antigen-specific CD8+ 
T cells that were expanded by an MVA boost and antibody responses that were boosted by 
protein antigen. The strongest responses were observed when multiple DREP primes were 
given. The two doses were, however, equally efficient as priming components. Whereas 
immunizing with gp140 without a prime induced a Th2-biased response characterized by 
IgG1 antibodies, mice that were primed with DREP displayed a more balanced Th1/Th2 
response with induction of both IgG1 and IgG2a antibodies. Thus, DREP promotes formation 
of Th1 type responses, in accordance with observations with conventional DNA vaccines and 
CHIKV DREP (83, 105, 200). 
When both MVA and protein were given as boosts, both T cells and antibodies directed at the 
antigen were induced. Accordingly, a CHIKV DREP prime followed by protein and MVA 
boost resulted in decreased disease progression compared to mice boosted with only one of 
the components, although a boost with only protein or MVA appeared to be sufficient for 
protection against viremia (83). No major differences were seen in paper III between the 
sequential and simultaneous MVA and protein/adjuvant boosts, both on the T cell and 
antibody responses. Another recent study used the same MVA and protein boosts, but instead 
after a non-replicon DNA prime. In that study, humoral responses were also similar when 
MVA and protein were given sequentially or simultaneously (134). T cell responses were, 
however, greater in magnitude when administering MVA and protein simultaneously. The 
increased response observed in that study may have been due to the higher dose of GLA-AF 
used, which could exert immunostimulatory effects that enhanced responses against MVA-
encoded immunogens. 
Another aspect that could be considered is whether there would be a difference in reversing 
the order of the sequential MVA-protein regimen. Here we administered MVA followed by 
protein, which in part mimics the RV144 HIV vaccine trial in which an ALVAC prime was 
given followed by a protein boost (77). One study showed that priming with gp140 protein 
formulated in IC31 adjuvant followed by a NYVAC boost induced Env-specific CD4+ and 
CD8+ T cell responses that were superior to those induced by the reversed order of protein 
and NYVAC administration (231). In paper III, the majority of observed antigen-specific T 
cells were directed at epitopes within Pol, with only weak responses against Env. This was in 
part a result of immunodominance that occurred when Env and Gag-Pol-Nef immunogens 
were given simultaneously encoded by DREP or MVA modalities. Thus, it is plausible that 
Env-specific responses could be increased by priming with Env, either as protein or encoded 
by DREP, without the presence of Gag-Pol-Nef, in order to focus immune responses towards 
Env. 
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3.3 ENHANCEMENT OF THE REPLICON BY INCORPORATION OF 
BACTERIAL FLAGELLIN 
Ligands of different PRRs may act in synergy to induce greatly augmented immune 
responses (146–150). In addition, it has been demonstrated that one of the most effective 
vaccines developed, the live attenuated yellow fever vaccine, stimulates multiple innate 
signaling pathways (59, 129, 130). We therefore asked in paper IV whether we could further 
enhance the immunogenicity of the replicon with additional PRR stimuli. We hypothesized 
that this could be achieved by incorporating flagellin, which stimulates cell surface-bound 
TLR5 and cytosolic NLRC4. Since VREP and flagellin stimulate different PRRs with 
different downstream pathways, they might act in synergy when co-administered and 
augment immune responses towards antigens expressed by VREP or co-immunized protein 
antigen. We therefore constructed VREP encoding FliC flagellin from Salmonella 
Typhimurium (VREP-FliC). 
3.3.1 Responses to replicon-encoded antigen 
Antigens expressed from VREP have previously been shown to induce antigen-specific 
antibody responses (201, 232, 233). To evaluate whether these responses could be augmented 
by the presence of flagellin, we immunized mice with VREP encoding the antigen mixed 
with either 1) VREP-FliC, 2) soluble FliC and control VREP encoding an irrelevant antigen, 
or 3) VREP encoding an irrelevant antigen. Three weeks after immunization, serum was 
assayed for antigen-specific IgG responses. No significant differences were observed 
between the groups. We additionally assessed antigen-specific CD8+ T cells with IFN-γ 
ELISpot on day 7 after immunization and observed no differences. 
Flagellin has been shown to act as an adjuvant when fused to the protein antigen, and an 
influenza vaccine based on a flagellin-antigen fusion protein is currently being evaluated in 
clinical trials (136–140). We therefore investigated whether flagellin might act as an adjuvant 
if expressed from VREP as a protein fused with the antigen. For this purpose, we produced 
VREP encoding a FliC-antigen fusion protein and immunized mice with this construct. No 
enhancement of antibody or CD8+ T cell responses were observed compared to immunizing 
with VREP encoding the antigen without flagellin. We then considered that it might be 
necessary for the fusion protein to be secreted from cells in order to obtain an adjuvant effect 
of flagellin, so we added a signal sequence for secretion on the fusion protein; however, this 
also had no effect on antigen-specific antibody responses. 
3.3.2 Responses to co-administered protein antigen 
It has previously been shown that VREP acts as an adjuvant for antigen-specific antibody 
responses when co-delivered with protein antigen (201, 202). We asked in paper IV whether 
this adjuvant effect could be further enhanced by incorporation of the flagellin gene into 
VREP. We therefore immunized mice with protein antigen mixed with either a control VREP 
encoding an irrelevant antigen, or with VREP-FliC. Three weeks after immunization, serum 
was assayed for antigen-specific IgG responses. Mice immunized with the VREP-FliC 
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adjuvant displayed a stronger IgG response than mice immunized with VREP not encoding 
flagellin. Whereas control VREP promoted IgG2a antibodies, VREP-FliC enhanced both 
IgG1 and IgG2a antibodies, indicating that VREP-FliC has an adjuvant effect on both Th1 
and Th2 type responses. Thus, we demonstrated that VREP expressing intracellular flagellin 
is a more potent adjuvant than VREP alone. 
We then asked whether the adjuvant effect of VREP-FliC was dependent on intracellular 
expression of FliC from the replicon, or whether administering soluble FliC together with 
VREP not expressing FliC would have a similar adjuvant effect. We immunized mice with 
protein antigen mixed with soluble FliC and VREP and did not observe an increased adjuvant 
effect on antigen-specific IgG responses compared to immunizing with soluble FliC protein 
or VREP on their own. 
We also investigated which innate signaling pathways are involved in the adjuvant effect of 
VREP-FliC. Type I IFN signaling has previously been shown to be crucial for the adjuvant 
effect of VREP (201). We showed that for VREP-FliC, IgG responses against co-immunized 
protein antigen were diminished but not abolished in mice lacking type I IFN signaling. This 
was likely due to the absence of contribution from VREP on inducing innate immunity. 
Similarly, we observed that the adjuvant effect of VREP-FliC in mice lacking TLR5 was 
diminished although not abrogated. In these mice, the VREP-FliC adjuvant did exert a 
stronger IgG response than the VREP adjuvant by itself, indicating that other pathways are 
also involved in the adjuvant effect of intracellularly expressed flagellin. 
For soluble flagellin, it has been reported that the adjuvant activity is codependent on TLR5 
and NLRC4, although TLR5 alone was necessary for the adjuvant effect of flagellin 
administered as a fusion protein with the antigen (234, 235). In addition, flagellin expressed 
from a vesicular stomatitis virus vector stimulates NLRC4 (144). Thus, it is likely that 
flagellin expressed intracellularly from VREP signals through NLRC4. Cells infected with 
VREP-FliC will eventually die from apoptosis due to VREP infection or pyroptosis due to 
NLRC4 signaling, which would release FliC into extracellular space, where it would be able 
to access TLR5 on cell surfaces. 
The difference in the adjuvant effect exerted by VREP expressing intracellular flagellin 
compared to VREP and soluble flagellin could be explained by timing and location. Infection 
of cells with VREP and amplification of replicon RNA is a process that takes several hours. 
Thus, for VREP encoding flagellin, stimulation of PRRs such as TLR3, TLR7, TLR8 and 
MDA5 by replicon RNA and TLR5 and NLRC4 by flagellin can occur at the same time and 
in the same cell. When VREP is instead administered with soluble flagellin, the flagellin is 
available for PRR stimulation immediately, and thus the effect of VREP and flagellin will not 
occur simultaneously. 
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4 CONCLUSIONS AND FUTURE PERSPECTIVES 
In this thesis, we characterized immune responses elicited by alphavirus replicons by 
immunizing mice or rhesus macaques and characterizing antigen-specific T cell and antibody 
responses. We demonstrated in paper I that T cell responses induced by DREP can be further 
elevated by delivery by i.d. EP. Responses were superior to those induced by a conventional 
DNA vaccine. We also established that a dose of 2 µg of DREP induced a maximal response. 
In paper II we showed that the kinetics of T cell responses induced by VREP or DREP 
exhibited a sharp peak followed by rapid contraction. To obtain an optimal effect of a 
booster, it was necessary to wait 3 weeks after prime until immune responses had contracted 
before administering a booster. Memory T cells were comprised of both Tem and Tcm 
subpopulations, and the Tem:Tcm ratio correlated with the dose given. We used the 
knowledge of optimal doses and timing obtained from papers I and II to assess DREP as a 
prime prior to a heterologous boost with MVA and/or protein antigen in paper III. DREP 
potently primed T cells that were expanded by an MVA boost and antibody responses that 
were boosted by protein antigen. These results in part confirmed our results in paper I, where 
we showed that DREP was superior to conventional plasmid DNA in priming T cells prior to 
a boost with MVA or ChAd63. Lastly, we took a different approach in paper IV, where we 
used VREP as an adjuvant for potentiating antibody responses against co-immunized protein 
antigen. We showed that this adjuvant effect could be further enhanced by incorporation of 
bacterial flagellin, which stimulates innate immune pathways different from those induced by 
VREP. 
Alphavirus replicons can be delivered as VREP, DREP or RREP. Which of these platforms is 
most attractive for future clinical use? The VREP vector is the alphavirus replicon platform 
that has been evaluated most extensively; however, several factors make the DREP and 
RREP approaches perhaps more favorable in a clinical setting. First, the production of VREP 
involves the use of cell lines, which is a complicated and expensive procedure that may 
hinder large-scale production. VREP based on SFV for preclinical use is produced in baby 
hamster kidney cell lines, which are not approved for GMP production. For clinical purposes, 
VREP would be prepared in Vero or 293 cell lines, which yield lower virus titers. Also, 
infectivity with viral particles may be decreased by antivector immunity in the host. 
Preexisting antivector immunity against SFV is not prevalent, and any antivector immune 
responses induced during immunization does not hinder the response to a homologous 
booster (188, 195–197). However, for safety reasons it is desirable to avoid induction of any 
irrelevant immune responses in a vaccine. 
We showed in this thesis that DREP is an excellent prime for T cell and antibody responses 
prior to a heterologous boost. However, RREP has certain benefits over DREP that may 
make it a more appealing vaccine platform such as the elimination of risk of integration into 
the host genome. The advances in delivery methods including EP and lipid nanoparticle 
formulation have shown to work well with RREP, inducing potent immune responses in mice 
and nonhuman primates (117, 211–213). The RREP platform has only recently gained 
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increased interest, and therefore data on its immunogenicity and use in prime-boost regimens 
is still limited. Further testing of RREP in heterologous prime-boost regimens in comparison 
to DREP would be valuable. 
Also, a systematic comparison of immune responses induced by different vaccine modalities 
including magnitude, breadth, memory phenotype and longevity will be valuable for design 
of vaccine regimens. Thus far, studies have combined vaccine vectors largely based on 
availability, and immunogenicity data has been difficult to compare due to differences in 
dosage, timing and antigens. A head-to-head comparison would be of great value for rational 
design of vaccine regimens. 
In conclusion, we have demonstrated that alphavirus replicons induce strong antigen-specific 
immune responses of both arms of adaptive immunity. In addition, we have characterized the 
kinetics and phenotypes of these responses allowing for tailoring of vaccination regimens. 
The results obtained in this thesis in addition to the past 20 years of preclinical testing of 
alphavirus replicons strongly support further development of these vectors in clinical trials. 
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